Evidence map›Paper›PMID 41301131›Full record

ReviewBioengineering (Basel, Switzerland)2025

Corneal Epithelial Tissue Engineering Strategy Based on Cell Viability Optimization: A Review and Prospects.

Guoguo Tang, Miaomiao Chi, Yang Zhai, Rongmei Peng, Jing Hong

Abstract readReview
In one paragraph

Review in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Guoguo TangDepartment of Ophthalmology, Peking University Third Hospital, Beijing 100191, China.ORCID 0009-0007-8504-8597
Miaomiao ChiDepartment of Ophthalmology, Peking University Third Hospital, Beijing 100191, China.
Yang ZhaiDepartment of Ophthalmology, Peking University Third Hospital, Beijing 100191, China.
Rongmei PengDepartment of Ophthalmology, Peking University Third Hospital, Beijing 100191, China.
Jing HongDepartment of Ophthalmology, Peking University Third Hospital, Beijing 100191, China.ORCID 0000-0002-8079-2073

Funding

National Natural Science Foundation of China 82371027
6 · The paper itself

Abstract

Corneal transplantation is often considered the last resort for severe corneal epithelial disorders, especially limbal stem cell deficiency (LSCD). Tissue engineering offers novel strategies to mitigate the shortage of corneal transplant donors. However, low cell viability and compromised functionality in tissue engineering represent a major challenge. In this review, we describe the key characteristics required for corneal epithelium bioscaffolds. We summarize the research progress centered on optimizing cell activity and functionality in the past 10 years from four key perspectives: the sourcing of cells, seed cell pretreatments, biomaterial optimization, and engineered culture system innovation. The sources, isolation, and induction methods of seed cells are described, and the advantages and disadvantages of existing clinical treatment methods are compared. Furthermore, we compare existing clinical therapies and summarize promising seed cell pretreatment strategies for the first time. Several innovative engineered cell culture systems are exhibited as well. We demonstrated how to preserve cell viability through bioscaffold stiffness modulation, topographic design, and application of innovative fabrication techniques. Finally, we propose a personalized and precise regeneration strategy based on high-resolution images, digital modeling, bioprinting, and machine learning.

Indexed as

biomaterialscorneal epitheliumlimbal stem cell deficiencytissue engineering

Identifiers

PMID41301131
PMCPMC12649728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.